(Y51) Drugs primarily affecting the autonomic nervous system

More details coming soon

Icon
17 073 in individuals diagnosis drugs primarily affecting the autonomic nervous system confirmed
Icon
507 deaths with diagnosis drugs primarily affecting the autonomic nervous system
Icon
3% mortality rate associated with the disease drugs primarily affecting the autonomic nervous system

Diagnosis drugs primarily affecting the autonomic nervous system is diagnosed Men are 43.77% more likely than Women

12 273

Men receive the diagnosis drugs primarily affecting the autonomic nervous system

0 (less than 0.1%)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
4 800

Women receive the diagnosis drugs primarily affecting the autonomic nervous system

507 (10.6 %)

Died from this diagnosis.

Risk Group for the Disease drugs primarily affecting the autonomic nervous system - Men aged 70-74 and Women aged 50-54

Icon
In Men diagnosis is most often set at age 0-5, 35-39, 50-84
Icon
Less common in men the disease occurs at Age 0-1, 5-34, 40-49, 85-95+Less common in women the disease occurs at Age 0-29, 35-49, 55-69, 75-79, 85-95+
Icon
In Women diagnosis is most often set at age 30-34, 50-54, 70-74, 80-84

Disease Features drugs primarily affecting the autonomic nervous system

Icon
Absence or low individual and public risk
Icon

Drugs primarily affecting the autonomic nervous system - what does this mean

Drugs primarily affecting the autonomic nervous system work by altering the activity of the autonomic nervous system, which controls involuntary bodily functions such as heart rate, digestion, respiration, and temperature regulation. these drugs can cause an imbalance in the autonomic nervous system, leading to symptoms such as dry mouth, constipation, dizziness, and fatigue.

What happens during the disease - drugs primarily affecting the autonomic nervous system

The primary pathogenesis of drugs affecting the autonomic nervous system is due to their direct effect on the neurotransmitters in the autonomic nervous system, which can result in either an excitatory or inhibitory response. this can lead to a variety of symptoms such as changes in heart rate, blood pressure, and sweating, as well as gastrointestinal disturbances, and can also affect the body's ability to regulate its temperature.

Clinical Pattern

More details coming soon

How does a doctor diagnose

  • Physical examination
  • Laboratory tests
  • Imaging studies
  • Autonomic reflex testing
  • Neurophysiological testing
  • Genetic testing
  • Cardiovascular monitoring
  • Neuropsychological testing

Treatment and Medical Assistance

Main goal of the treatment: To reduce the symptoms of the disease and improve the functioning of the autonomic nervous system.
  • Prescribing medications that act on the autonomic nervous system, such as beta blockers, clonidine, and other drugs.
  • Encouraging lifestyle changes, such as reducing stress, eating a healthy diet, and getting regular exercise.
  • Counseling and psychotherapy to help patients cope with their symptoms.
  • Biofeedback and relaxation techniques to help reduce stress.
  • Physical therapy to help improve strength and flexibility.
Icon
8 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Drugs primarily affecting the autonomic nervous system - Prevention

The best way to prevent drugs primarily affecting the autonomic nervous system is to avoid taking any drugs that may have an effect on the autonomic nervous system, such as stimulants, depressants, and hallucinogens. additionally, it is important to be aware of any potential side effects of medications and to talk to a doctor before taking any medications.

Specified forms of the disease

(Y51.0) Anticholinesterase agents
(Y51.1) Other parasympathomimetics [cholinergics]
(Y51.2) Ganglionic blocking drugs, not elsewhere classified
(Y51.3) Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified
(Y51.4) Predominantly alpha-adrenoreceptor agonists, not elsewhere classified
(Y51.5) Predominantly beta-adrenoreceptor agonists, not elsewhere classified
(Y51.6) Alpha-adrenoreceptor antagonists, not elsewhere classified
(Y51.7) Beta-adrenoreceptor antagonists, not elsewhere classified
(Y51.8) Centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified
(Y51.9) Other and unspecified drugs primarily affecting the autonomic nervous system